Nhà đầu tư - Imexpharm

Financial information

IMP - Press release: Imexpharm Corporation announces first quarter 2025 results

IMP - Financial Statement Q1. 2025

IMP - Audited Financial Statements for the year end 31 Dec 2024

IMP - 2M2025 Business Updates

Imexpharm - VAD investor presentation

IMP - 4Q2024 and FY2024 business results

Imexpharm Facts & Figures 2024

IMP - Press release: Imexpharm Corporation announces 4Q2024 and FY2024 business results

IMP - Financial Statements Q4. 2024

IMP - Press release: Imexpharm Corporation announces first quarter 2025 results

IMP - 2M2025 Business Updates

Imexpharm - VAD investor presentation

IMP - 4Q2024 and FY2024 business results

Imexpharm Facts & Figures 2024

IMP - Press release: Imexpharm Corporation announces 4Q2024 and FY2024 business results

IMP - Imexpharm 4Q2024 Earnings Call Invitation

IMP - 11M2024 Business Updates

IMP - 10M2024 Business Updates

IMP - Financial Statement Q1. 2025

IMP - Audited Financial Statements for the year end 31 Dec 2024

IMP - Financial Statements Q4. 2024

IMP - Financial Statements Q3. 2024

IMP - Explanation of 1H2024 financial statements

IMP - Reviewed Interim Financial Statements 1H2024

IMP - Explanation of 2Q2024 financial statements

IMP - Financial Statement Q2. 2024

IMP - Explanation of 1Q2024 financial statements

Annual Report & Sustainability Report

Annual Report 2024

Annual Report 2024

Sustainability Report 2023

Sustainability Report 2023

Annual Report 2023 (Digital version)

Annual Report 2023 (Digital version)

Annual Report 2023 (PDF version)

Annual Report 2023 (PDF version)

Sustainability Report 2022

Sustainability Report 2022

Annual Report 2022

Annual Report 2022

Sustainability Report 2021

Sustainability Report 2021

Annual Report 2021

Annual Report 2021

Sustainability Report 2020

Sustainability Report 2020

Annual Report 2024

Annual Report 2024

Annual Report 2023 (Digital version)

Annual Report 2023 (Digital version)

Annual Report 2023 (PDF version)

Annual Report 2023 (PDF version)

Annual Report 2022

Annual Report 2022

Annual Report 2021

Annual Report 2021

Annual Report 2020

Annual Report 2020

Annual Report 2019

Annual Report 2019

Annual Report 2018

Annual Report 2018

Annual Report 2017

Annual Report 2017

Sustainability Report 2023

Sustainability Report 2023

Sustainability Report 2022

Sustainability Report 2022

Sustainability Report 2021

Sustainability Report 2021

Sustainability Report 2020

Sustainability Report 2020

Sustainability Report 2019

Sustainability Report 2019

Sustainability Report 2018

Sustainability Report 2018

AGM

IMP - Documents for the 2025 Annual General Meeting of Shareholders

04/03/2025

IMP - Announcement attend the AGM 2025

03/28/2025

IMP - Resolution of the GMS No. 04 approving the implementation of the Cat Khanh Pharmaceutical Factory Complex Project

10/30/2024

IMP - Resolution of the GMS No. 03 approving certain issues by collecting written opinions

10/30/2024

IMP - Minutes of voting checking results of shareholders' written opinions (2nd time in 2024)

10/30/2024

IMP - Documents to collect GMS's opinions in writing (2nd time in 2024)

10/17/2024

IMP - Resolution of the GMS to collect shareholders' written opinions

08/08/2024

IMP - Minutes of voting checking results of shareholders' written opinions

08/08/2024

IMP - Documents for the 2025 Annual General Meeting of Shareholders

04/03/2025

IMP - Announcement attend the AGM 2025

03/28/2025

IMP - Documents to collect GMS's opinions in writing (2nd time in 2024)

10/17/2024

IMP - Documents to collect GMS's opinions in writing

07/25/2024

IMP - Documents of the 2024 AGM

04/05/2024

IMP - Announcement attend the AGM 2024

03/26/2024

IMP - Document for obtaining written opinions of the GMS 2023

11/27/2023

IMP - Invitation and Documents of the 2023 AGM

03/29/2023

IMP - Resolution of the GMS No. 04 approving the implementation of the Cat Khanh Pharmaceutical Factory Complex Project

10/30/2024

IMP - Resolution of the GMS No. 03 approving certain issues by collecting written opinions

10/30/2024

IMP - Minutes of voting checking results of shareholders' written opinions (2nd time in 2024)

10/30/2024

IMP - Resolution of the GMS to collect shareholders' written opinions

08/08/2024

IMP - Minutes of voting checking results of shareholders' written opinions

08/08/2024

IMP - AGM 2024 Resolution

04/27/2024

IMP - AGM 2024 Minutes

04/27/2024

IMP - Minutes of vote counting and Resolution of the GMS to collect written opinions

12/19/2023

Corporate Governance

IMP - Report on Corporate Governance for 2024

01/23/2025

IMP - Imexpharm's Charter - October 2024

10/01/2024

IMP - Report on Corporate Governance for 1H2024

07/30/2024

IMP - Imexpharm's Charter - July 2024

07/29/2024

Imexpharm’s Internal regulations on corporate governance - April, 2024

04/27/2024

IMP - Imexpharm's Charter - April 2024

04/27/2024

IMP: Report on Corporate Governance in 2023

01/30/2024

IMP - Imexpharm' s Charter - Oct 2023

10/27/2023

IMP - Imexpharm's Charter - October 2024

10/01/2024

IMP - Imexpharm's Charter - July 2024

07/29/2024

Imexpharm’s Internal regulations on corporate governance - April, 2024

04/27/2024

IMP - Imexpharm's Charter - April 2024

04/27/2024

IMP - Imexpharm' s Charter - Oct 2023

10/27/2023

IMP: Imexpharm Corporation's internal regulations on corporate governace 04/2023

04/29/2023

IMP - Imexpharm's Charter - April 2023

04/29/2023

IMP: Charter of the Board of Directors 04/2023

04/29/2023

IMP - Report on Corporate Governance for 2024

01/23/2025

IMP - Report on Corporate Governance for 1H2024

07/30/2024

IMP: Report on Corporate Governance in 2023

01/30/2024

IMP: Report on Corporate Governance for the First 6 months of 2023

07/28/2023

IMP – Report on Corporate Governance in 2022

01/30/2023

IMP - Report on Corporate Governance for 1H2022

07/25/2022

IMP – Report on Corporate Governance in 2021

01/24/2022

IMP - Report on Corporate Governance for 1H2021

07/27/2021

Imexpharm – Prospectus for Public Offering of Shares 2010

11/16/2010

Information Disclosure

IMP - Financial Statement Q1. 2025

04/18/2025

IMP - Announcement of the link to the 2024 Annual Report

04/09/2025

IMP - BOD Resolution No.03 on the purchase of D&O Insurance for 2025

04/03/2025

IMP - BOD Resolution No.03 on the approval of the 2025 Credit Line

04/03/2025

IMP - Disclosure of 2025 AGM Documents

04/03/2025

IMP - Announcement of Time, Venue, and link to access the Agenda of the 2025 AGM

03/28/2025

IMP - Disclosure on Land Lease Payment at Quang Khanh Industrial Cluster for IMP5 Project

03/11/2025

IMP - HOSE announces the record date to close the list of shareholders attending the 2025 AGM

03/03/2025

Analyst Report

Analyst Report

PHS - Company meeting note

SSI - Positive Outlook for 2H and Beyond

VDSC - Business update 1Q2024

Vietcap - Visit note

FPTS - Valuation update report

ACBS - Flash Note IMP

PHS - Flash Note

VDSC - Pharmaceutical industry 2024

SSI - Climbing new heights

News - Events

4Q & FY2024 - Imexpharm Facts & Figures

02/11/2025

4Q & FY2024 - Imexpharm Facts & Figures

Imexpharm 2024 business results recap video

01/24/2025

Imexpharm 2024 business results recap video

Imexpharm 4Q2024 Earnings Call Invitation

Imexpharm 4Q2024 Earnings Call Invitation

01/15/2025

Imexpharm Honored in the Vietnam’s 50 Best Performing Companies for 2024

Imexpharm Honored in the Vietnam’s 50 Best Performing Companies for 2024

12/11/2024

Imexpharm: Growing More Strongly Than the Industry

Imexpharm: Growing More Strongly Than the Industry

11/08/2024

3Q2024 - Imexpharm Facts & Figures

3Q2024 - Imexpharm Facts & Figures

11/07/2024

Top 50 best listed companies

Top 50 best listed companies

In 2024, Imexpharm was voted Top 50 best listed companies of the year by Forbes Vietnam Magazine. Being named on the list for the third time, Imexpharm shows its solid preparation of internal strength, ready for the next steps on its 47-year development journey.